Valneva SE (VALN) Form 6-K — Oct 15, 2026

Valneva SE announced on October 14, 2026 that senior management will present and hold investor meetings at four upcoming U.S. and European healthcare conferences, including the Guggenheim, Stifel, and Jefferies November events. The fireside chats will focus on the regulatory outlook for the company's Lyme disease vaccine candidate, which is partnered with Pfizer, with regulatory decisions expected within the next 12 months.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.